secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2026-10-02T11:30:27+00:00
Accession:  0001193125-26-411260
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4.1-flash:cloud@v2

Quince Therapeutics board overhaul: 3 directors to resign, 4 named pending Oct 6 vote
--------------------------------------------------------------------------------

- Directors June Bray, David Lamond and Christopher Senner conditionally resigned effective two business days after the Oct 6, 2026 Special Meeting; no disagreement with the Company cited.
- Board seats contingent on approval of three proposals: Series C conversion (>20% of shares outstanding), Minimum Price Proposal, and raising authorized shares from 250M to 275M.
- Incoming directors: Catherine Bonuccelli (Class I; Audit, Comp), Leone Patterson (Class III; chair Audit & Comp), James Valentine (Class I; chair NomGov), Drayton Wise (Class II; NomGov).
- Conversion Proposal may, together with certain management and board changes, result in a change of control under Nasdaq Listing Rule 5635(b).
- Incoming directors' backgrounds: Bonuccelli ex-Bellus Health CMO; Patterson ex-CFO Zymeworks and Tenaya; Wise ex-CCO Insmed; Valentine director at Hyman, Phelps & McNamara.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526411260/0001193125-26-411260-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526411260/d171747d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-411260

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer